TRAVERE THERAPEUTICS, INC. — Key Metrics
2 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-0
Book Value Per Share
$1
Free Cash Flow Per Share
$0
Cash Per Share
$1
Revenue Per Share
$6
OCF Per Share
$0
Return on Equity
-29.4%
Return on Assets
-4.3%
Return on Invested Capital
-57.1%
Current Ratio
2.74
Quick Ratio
2.51
Asset Turnover
0.82
Days Sales Outstanding
59.60
Days Payables Outstanding
875.52
Days Inventory On Hand
1276.39
Cash Conversion Cycle
460.47
R&D / Revenue
42.0%
SBC / Revenue
9.1%
Capex / Revenue
—
Working Capital
$278M
Net Current Asset Value
$-53M
Invested Capital
$115M
OCF / Net Income
-1.48
FCF / Net Income
-1.48
Accruals Ratio (Sloan)
-10.5%
Net Debt
$-93M
Net Debt / EBITDA
44.71
Interest Coverage
-5.85
Cash Coverage
3.52
Capex Coverage
—
Tangible Common Equity
$960K
TCE / Total Assets
0.2%
Goodwill / Total Assets
0.1%
NOPAT
$-50M
Cash ROIC
43.5%
WC / Revenue
56.6%
Capex / D&A
—
Reinvestment Rate
96.7%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
-108.6%
Revenue 5Y CAGR
19.9%
Book Value 5Y CAGR
-11.5%
Stock Price (FY-end)
$38
Market Cap
$3.41B
P/E Ratio
—
P/S Ratio
6.95
P/B Ratio
29.69
P/TB Ratio
3550.82
P/OCF Ratio
90.22
P/FCF Ratio
90.22
Enterprise Value
$3.32B
EV / Sales
6.76
EV / FCF
87.76
FCF Yield
1.1%
Shareholder Yield
-1.3%
Buyback Yield
—
R&D Yield
6.0%
Capex Yield
—
Graham Number
—
Shares Variation (YoY)
13.1%
Beta (5Y)
1.14
Cost of Equity
10.2%
52W High
$40
52W Low
$13
Trailing Return 1Y
121.1%
Trailing Return 5Y
37.1%
F-Score (Piotroski)
6.00
Z-Score (Altman)
1.78
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.